Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure

International Journal of Clinical Practice

Volumn 61, Issue 4, 2007, Pages 603-610

  Fragasso, G ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; ETOMOXIR; FATTY ACID; GLUCOSE; INSULIN; MOXONIDINE; OXFENICINE; OXYGEN; PERHEXILINE; PHOSPHATE; PLACEBO; RANOLAZINE; TRIACYLGLYCEROL; TRIMETAZIDINE;

CLINICAL TRIAL; DIABETES MELLITUS; EXERCISE TOLERANCE; FATTY ACID METABOLISM; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LITERATURE; MORTALITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL GLUCOSE TOLERANCE TEST; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STRESS ECHOCARDIOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; CARDIOVASCULAR AGENTS; ENDOTHELIUM, VASCULAR; FATTY ACIDS, NONESTERIFIED; HEART FAILURE; HUMANS; MYOCARDIUM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33947419296     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01280.x     Document Type: Review

References (77)

1. Oliver MF. Glucose, insulin, potassium in acute myocardial infarction. Acta Cardiol 1973; 28 (Suppl. 17): 257-66.
2. Vik-Mo H, Riemersma RA, Mjos OD et al. Effect of myocardial ischemia and antilipolytic agents on lipolysis and fatty acid metabolism in the in situ dog heart. Scand J Clin Lab Invest 1979; 39: 559-68.
3. Lewis CM, Brink AJ. Beta adrenergic blockade. Hemodynamics and myocardial energy metabolism in patients with ischemic heart disease. Am J Cardiol 1968; 21: 846-59.
4. Armstrong PW, Chiong MA, Parker JO. Effects of propranolol on the hemodynamic, coronary sinus blood flow and myocardial metabolic response to atrial pacing. Am J Cardiol 1977; 40: 83-9.
5. Mc Veigh JJ, Lopaschuck GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 1990; 259: H1070-85.
6. Nicholl TA, Lopaschuck GD, McNeill GH. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat hearts. Am J Physiol 1991; 261: H1053-9.
7. Bersin RM, Wolfe C, Kwasman M et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994; 23: 1617-24.
8. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 1972; 15: 289-329.
9. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26: 949-58.
10. Kantor PF, Lucien A, Kozak R, Lopashuck GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
11. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003; 93: e26-32.
12. MacInness A, Fairman DA, Binding P et al. The antianginal trimetazidine does not exert its functional benefit via inhibition of mitocondrial long chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003; 93: e33-7.
13. Antzelevitch C, Belardinelli L, Zygmunt AC et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904-10.
14. Lopaschuck GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation 1997; 95: 313-5.
15. Lommi J, Kupari M, Koskinen P et al. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 1996; 28: 665-72.
16. Riley M, Bell N, Elborn JS, Stanford CF, Buchanan KD, Nicholls DP. Metabolic response to graded exercise in chronic heart failure. Eur Heart J 1993; 14: 1484-8.
17. Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic heart failure. Metabolism 1991; 40: 972-7.
18. Nuutila P, Knuuti MJ, Raitakari M et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol 1994; 267: E941-6.
19. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-29.
20. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623-34.
21. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990; 11: 207-12.
22. Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901.
23. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001; 22: 2164-70.
24. Fragasso G, Piatti PM, Monti L et al. Short and long term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy. Am Heart J 2003; 146: E1-8.
25. Rosano GMC, Vitale C, Sposato B et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003; 2: 16/1-/9.
26. Vitale C, Wajngaten M, Sposato B et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25: 1814-21.
27. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161-5.
28. Lavanchy N, Martin J, Rossi A. Anti-ischemia effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97-110.
29. 31P magnetic resonance spectroscopy. Lancet 1991; 338: 973-6.
30. Yabe T, Mitsunami K, Inubushi T, Kinoshita M. Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation 1995; 92: 15-23.
31. Nascimben L, Ingwall JS, Pauletto P et al. The creatine kinase system in failing and nonfailing human myocardium. Circulation 1996; 94: 1894-901.
32. Fragasso G, De Cobelli F, Perseghin G et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27: 942-8.
33. Neubauer S, Horn M, Cramer M et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96: 2190-6.
34. Fragasso G, Palloshi A, Puccetti P et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-8.
35. Sabbah HN, Chandler MP, Mishima T et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002; 8: 416-22.
36. Chandler MP, Stanley WC, Morita H et al. Short-term treatment with ranolazine improves mechanical efficacy in dogs with chronic heart failure. Circ Res 2002; 91: 278-80
37. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994; 5: 741-7.
38. Aaker A, McCormack JG, Hirai T, Musch TI. Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. J Cardiovasc Pharmacol 1996; 28: 353-62.
39. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004; 364: 1786-8.
40. Opie LH. The metabolic vicious circle in heart failure. Lancet 2004; 364: 1733-4.
41. Piatti PM, Monti LD, Galli L et al. Relationship between endothelin-1 concentrations and the metabolic alterations typical of the insulin resistance syndrome. Metabolism 2000; 49: 748-52.
42. Piatti PM, Monti LD, Zavaroni I et al. Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. J Clin Endocrinol Metab 2000; 85: 2416-20.
43. Crettaz M, Zaninetti D, Jeanrenaud B. Insulin-resistance in heart and skeletal muscles of genetically obese Zucker rats. Biochem Soc Trans 1981; 9: 524-5.
44. Natali A, Taddei S, Quiñones Galvan A et al. Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. Circulation 1997; 96: 725-6.
45. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7.
46. Piatti PM, Fragasso G, Monti LD et al. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. J Am Coll Cardiol 1999; 34: 1452-60.
47. Piatti P, Di Mario C, Monti LD et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003; 108: 2074-81.
48. The Decode Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21.
49. Wallhaus TR, Taylor M, DeGrado TR, Russell DC. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001; 103: 2441-6.
50. Podbregar M, Voga G. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Card Fail 2002; 8: 369-78.
51. Poole-Wilson PA, Swedberg K, Cleland JGF et al. and COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET) randomised controlled trial. Lancet 2003; 362: 7-13.
52. Cohn JN, Pfeffer MA, Rouleau J et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659-67.
53. Mobini R, Jansson PA, Bergh CH, Sharing Tang M, Waagstein F, Andersson B. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine. Clin Sci 2006; 110: 329-36.
54. Cano C, Bermú dez VJ, Medina MT et al. Trimetazidine diminishes fasting glucose in rats with fasting hyperglycemia: a preliminary study. Am J Ther 2003; 10: 444-6.
55. Monti LD, Setola E, Fragasso G et al. Metabolic and endothelial effects of trimetazidine on forearm muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab 2006; 290: E54-9.
56. Fragasso G, Piatti P, Monti L et al. Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine. J Am Coll Cardiol 2002; 39: 413-9.
57. Yamauchi-Kohno R, Miyauchi T, Hoshino T et al. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin production in the heart and bene-ficial effect of endothelin A antagonist on survival and cardiac function. Circulation 1999; 99: 2171-6.
58. Maridonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985; 20: 148-51.
59. Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291: 309-16.
60. 1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27: 42-8.
61. Lopashuck GD, Wall SR, Olley PM, Davies NJ. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988; 63: 1036-43.
62. Ratheiser K, Schneeweiss B, Waldhausl W et al. Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. Metabolism 1991; 40: 1185-90.
63. Turcani M, Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 1997; 96: 3681-6.
64. Zarain-Herzberg A, Rupp H. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin Investig Drugs 2002; 11: 345-56.
65. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000; 99: 27-35.
66. Schmitz FJ, Rösen P, Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor etomoxir. Horm Metab Res 1995; 27: 515-22.
67. Cabreros A, Merlos M, Laguna JC, Carrera MV. Down-regulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy. J Lipid Res 2003; 44: 388-98.
68. Merril CL, Ni H, Yoon LW et al. Etomoxir-induced oxidative stress in HepG2 cells detected by differential gene expression is confirmed biochemically. Toxicol Sci 2002; 68: 93-101.
69. Kennedy JA, Kiosoglus AJ, Murphy GA, Pelle MA, Horowitz JD. Effect of perhexilline and oxfenicine on myocardial function and metabolism during low flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2000; 36: 794-801.
70. Jeffrey FM, Alvarez L, Diczku V, Sherry AD, Mallory CR. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 1995; 25: 469-72.
71. Stephens TW, Higgins AJ, Cook GA, Harris RA. Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem J 1985; 227: 651-60.
72. Bergman G, Atkinson L, Metcalfe J, Jackson J, Jewitt DE. Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (l-hydroxyphenylglycine) in angina pectoris. Eur Heart J 1980; 1: 247-53.
73. Cole PL, Beamer AD, McGowan N et al. Efficacy and safety of perhexiline maleate in refractory angina: a double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81: 1260-70.
74. Lee L, Campbell R, Scheuermann-Freestone M et al. Metabolic modulation with perhexiline in chronic heart failure. A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005; 112: 3280-8.
75. Meier C, Wahllaender A, Hess CW, Preisig R. Perhexiline-induced lipidosis in the dark Agouti (DA) rat: an animal model of genetically determined neurotoxicity. Brain 1986; 109: 649-60.
76. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001; 1: 193-204.
77. Jackson G. Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosis. Int J Clin Pract 2006; 60: 891-2.